RevvityRVTY
RVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more call options, than puts
Call options by funds: $1.93M | Put options by funds: $1.16M
18% more repeat investments, than reductions
Existing positions increased: 199 | Existing positions reduced: 168
14% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 50
2.42% more ownership
Funds ownership: 91.52% [Q4 2024] → 93.94% (+2.42%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
0% less funds holding
Funds holding: 519 [Q4 2024] → 518 (-1) [Q1 2025]
10% less capital invested
Capital invested by funds: $13.2B [Q4 2024] → $11.9B (-$1.28B) [Q1 2025]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$100
1%
downside
Avg. target
$114
12%
upside
High target
$125
23%
upside
8 analyst ratings
6 positive
75%
2 neutral
25%
0 negative
0%
Evercore ISI Group Vijay Kumar | 13%upside $115 | Outperform Maintained | 8 Jul 2025 |
B of A Securities Derik De Bruin | 8%upside $110 | Buy Maintained | 26 Jun 2025 |
UBS Dan Leonard | 13%upside $115 | Buy Upgraded | 1 May 2025 |
Goldman Sachs Matthew Sykes | 23%upside $125 | Buy Maintained | 29 Apr 2025 |
JP Morgan Rachel Vatnsdal | 1%downside $100 | Neutral Maintained | 29 Apr 2025 |
Financial journalist opinion
Neutral
Business Wire
4 days ago
Revvity to Hold Earnings Call on Monday, July 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of t.
Positive
Finbold
1 month ago
Missed Tempus AI rally? 2 tech healthcare stocks to buy now
Tempus AI (NASDAQ: TEM) has taken Wall Street by storm, ranking among the best-performing equities of 2025.
Neutral
Business Wire
1 month ago
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requi.
Positive
Zacks Investment Research
1 month ago
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Neutral
Business Wire
1 month ago
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 in.
Negative
Seeking Alpha
2 months ago
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the company maintained full-year guidance. While I rate Revvity a buy, it faces some structural challenges longer-term.
Neutral
Business Wire
2 months ago
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic pri.
Positive
Zacks Investment Research
2 months ago
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Neutral
Seeking Alpha
2 months ago
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
Neutral
Zacks Investment Research
2 months ago
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charts implemented using Lightweight Charts™